Cardio Diagnostics CEO Discusses India Expansion and Medicare Progress in BioMedWire Podcast

Cardio Diagnostics Holdings (NASDAQ: CDIO) took center stage in the latest episode of The BioMedWire Podcast, with CEO and Co-Founder Dr. Meesha Dogan discussing the company's mission to improve cardiovascular disease prevention and early detection through precision medicine. Leveraging epigenetics, genetics, and artificial intelligence, Cardio Diagnostics aims to make cardiovascular care more accessible and personalized. During the interview, Dogan highlighted the company's expansion into India through partnerships with Aimil Ltd. and Dr. Lal PathLabs, as well as progress through the Medicare reimbursement process. She noted that CPT coding and payment steps have been completed, while coverage determination remains underway.

The company's core technology, an AI-driven Integrated Genetic-Epigenetic Engine, powers clinical tests designed to enhance prevention, detection, and management of cardiovascular disease. This technology is central to Cardio Diagnostics' strategy to become a leading medical technology company in the cardiovascular space. The expansion into India represents a significant milestone, as the partnerships with Aimil Ltd. and Dr. Lal PathLabs are expected to bring these advanced diagnostic tools to a broader population. Meanwhile, progress through the Medicare reimbursement process is critical for making the tests accessible to U.S. patients covered by Medicare, with coverage determination being the final step.

The podcast appearance underscores Cardio Diagnostics' commitment to transparency and investor communication. The full press release is available at https://ibn.fm/8DJcl. For the latest news and updates relating to CDIO, the company maintains a newsroom at https://ibn.fm/CDIO. This announcement comes via MissionIR, a specialized communications platform within the Dynamic Brand Portfolio @IBN, which provides syndicated content to enhance visibility for companies in the investment community.

Cardio Diagnostics' focus on precision medicine and AI-driven diagnostics positions it at the forefront of cardiovascular healthcare innovation. The company's ability to navigate regulatory and reimbursement pathways while expanding internationally indicates a robust growth trajectory. As cardiovascular disease remains a leading cause of death globally, advancements in early detection and personalized treatment are of paramount importance. The progress reported in the podcast, particularly the India expansion and Medicare reimbursement steps, suggests that Cardio Diagnostics is making tangible strides toward broader market access and clinical adoption.